InsidersTradesSigma
Follow the Syndax Pharmaceuticals, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.4bn. The latest transaction was disclosed on 8 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: MICHAEL METZGER. All data is free.
Analysts rate Syndax Pharmaceuticals, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for cancer. It specializes in targeted therapies and immunotherapies.